/Companies

Ocugenix

Pittsburgh, US · Founded 2015 · Delaware corporation

Find your way into Ocugenix

Each arrow is one introduction. Sign up to fill in the first one.

416 people can intro you to Sean

Ask Robert Reilly to introduce you to Sean McDonald

You →Robert · together at Aethon →Sean

Sign up to find every way you can get introduced to Ocugenix

  • Your email: who you already know at Ocugenix, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Ocugenix team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Ocugenix is a biotechnology company developing ophthalmology therapeutics based on NIH-funded research into the molecular mechanisms of wound healing and cellular response, originating from a research team at the University of Pittsburgh Medical Center. Its focus areas include eye diseases such as glaucoma and retinal conditions.

Founders & leadership

Ocugenix was founded in 2015 by Sean McDonald.

SMSean McDonald
Sean McDonaldFounder · President & CEOSean McDonald is Chief Executive Officer and co-founder of Ocugenix, a biotechnology company developing therapeutics for eye diseases including glaucoma and wet macular degeneration. He previously served as President and CEO of Precision Therapeutics, where he built a personalized medicine company, and held leadership roles at McKesson and as founder of Automated Healthcare, a robotics-based pharmacy automation company.
AWAlan Wells
Alan WellsChief Scientific Officer
RS
Richard S. KollenderNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$1.6M disclosed across 2 rounds · 2019–2021

▶$1.3MraisedSep 2021 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard S. KollenderDirector
  • Sean McDonaldExecutive Officer, Director
  • Paul USA ChaneyDirector
  • Thomas C. HohmanDirector
Offering amount
$4M
Amount sold
$1.3M
First sale
Jul 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$350KraisedOct 2019 · 6 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Sean McDonaldExecutive Officer, Director
  • Richard S. KollenderDirector
Offering amount
$350K
Amount sold
$350K
First sale
Aug 2019
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

Companies working in the same space as Ocugenix.

Frequently asked questions

What does Ocugenix do?
Ocugenix is a biotechnology company developing ophthalmology therapeutics based on NIH-funded research into the molecular mechanisms of wound healing and cellular response, originating from a research team at the University of Pittsburgh Medical Center. Its focus areas include eye diseases such as glaucoma and retinal conditions.
Who founded Ocugenix?
Ocugenix was founded by Sean McDonald in 2015.
How much funding has Ocugenix raised?
Ocugenix has disclosed $1.6M raised across 2 rounds.
Where is Ocugenix headquartered?
Ocugenix is headquartered in Pittsburgh, US.